Sudden vision loss in one eye needs same-day care. Call an eye doctor or go to the emergency department.

Hazleton Eye Specialists · Office 570-453-2020 · Fax 570-453-1020

Optic Nerve Health

Referring providers: Refer a patient or ask a question · Same-day: 570-453-2020

Schedule an exam

Home For Prescribers Papilledema and IIH in patients on GLP-1 medicines

Papilledema and IIH in patients on GLP-1 medicines

Recognition, triage, and what the evidence shows

Reviewed by Dr. James Deom, OD, MPH, FAAO, FSLS, Chief of Eye Care Services, Hazleton Eye Specialists Last reviewed: November 12, 2026 Audience: Prescribers

Same-day care

Sudden vision loss in one eye needs same-day care.

Call an eye doctor or go to the emergency department.

Call the office 570-453-2020Find an eye doctor 5 officesSchedule an exam Pick your office

Many patients prescribed GLP-1 receptor agonists for obesity share the demographic profile of idiopathic intracranial hypertension (IIH): women of reproductive age with obesity or recent weight gain.¹ ² This page covers recognizing papilledema in that group, telling it apart from NAION, and what is known about GLP-1 RAs in IIH. Background for patients is on Papilledema and IIH.

The short version

  • Headache is a common GLP-1 RA side effect, but new or changed headache with transient visual obscurations, pulsatile tinnitus, or diplopia should prompt a dilated eye exam within days, not attribution to the medicine.
  • Bilateral disc swelling is papilledema until proven otherwise and needs urgent neuro-imaging (MRI with MRV) to exclude a mass or venous sinus thrombosis.¹
  • Weight loss is part of IIH treatment.² ³ GLP-1 RAs are being studied in IIH but are not FDA-approved for IIH.⁴
  • Sudden vision loss in one eye points toward NAION or another acute cause and needs same-day evaluation.

Papilledema versus NAION

Feature Papilledema (IIH) NAION
Eyes Usually both Usually one at onset
Vision Often normal early; transient obscurations; field loss with chronic or severe disease Sudden painless loss of acuity or field, often noticed on waking
Typical patient Younger, often female, obesity or recent weight gain Usually over 50; vascular risk factors; small crowded disc
Other symptoms Headache, pulsatile tinnitus, diplopia (CN VI) Usually none; headache suggests other causes, including GCA
Work-up Urgent MRI/MRV, then LP with opening pressure Same-day eye exam; exclude GCA if over 50

Medicines and conditions associated with raised intracranial pressure

Revised diagnostic criteria list secondary causes, including tetracycline-class antibiotics, vitamin A and retinoids, and withdrawal of corticosteroids, among others, along with venous sinus thrombosis.¹ Review the medication list in any patient with suspected papilledema.

GLP-1 RAs and IIH: what the evidence shows

  • Weight loss: the IIH:WT randomized trial found bariatric surgery lowered intracranial pressure more than a community weight-management program at 12 months, supporting sustained weight loss as disease-modifying.³ The IIH Treatment Trial combined acetazolamide with a low-sodium weight-reduction diet.⁵
  • Direct effect: in a randomized, placebo-controlled trial in 16 women with active IIH, exenatide lowered ICP measured by telemetric monitoring at 2.5 hours, 24 hours, and 12 weeks.⁴ The authors called for a phase 3 trial. This is preliminary evidence, not a basis for routine use.
  • Weight regain after stopping weight-loss treatment could plausibly be followed by relapse, given the role of weight in IIH.² Patients with IIH who stop a GLP-1 RA should keep eye and neurology follow-up. (This point is an inference from the weight-loss evidence, not a finding of a GLP-1 trial.)

Suggested approach for prescribers

  1. Ask GLP-1 RA patients with new or changed headache about transient visual obscurations, pulsatile tinnitus, and diplopia.
  2. If present, arrange a dilated eye exam within days; same day if vision is reduced.
  3. If disc swelling is found, coordinate urgent MRI/MRV and neurology.
  4. In known IIH, coordinate any GLP-1 RA decision with the treating neurologist or neuro-ophthalmologist, and keep visual field and OCT monitoring on schedule.

Dr. Deom’s recommendation (clinical opinion / practice recommendation)

Dr. James Deom recommends that everyone starting or taking a GLP-1 medication have a comprehensive dilated eye exam with OCT, OCT angiography (OCTA), and retinal photography (fundus photos with autofluorescence) as a baseline and for follow-up, and seek same-day care for sudden vision loss.

This is his clinical opinion and practice recommendation, not a society mandate. AAO and NANOS do not recommend routine examination solely to predict NAION, and no exam or imaging test reliably predicts or prevents an acute event. The baseline is intended to document disc anatomy and retinal status for later comparison and to detect other eye disease. See the study comparison for where professional positions agree and differ.

Dr. James Deom’s personal clinical thought

This is his opinion, not established evidence. It is not a finding from the studies or a position of the FDA, EMA, AAO, NANOS, or AOA.

As patients lose weight and their overall health improves on GLP-1 medicines, blood pressure and cholesterol medicines are often not re-addressed. Over-treatment of blood pressure may lead to hypotension, which can worsen at night and could cause nighttime hypoperfusion of the optic nerve. That sequence would fit the typical presentation of NAION (vision loss noticed on waking).

He recommends that people on GLP-1 medicines also improve exercise and diet, and keep regular visits with their usual doctors, even if that clinician did not prescribe the GLP-1, so the rest of their care, including blood pressure, is maintained.

For prescribers: consider reviewing antihypertensive dosing and timing (including bedtime dosing) as weight drops. Coordinate changes with the patient’s usual clinician when someone else wrote the GLP-1 prescription.

How to reach us

Same-day evaluation: providers can call the office at 570-453-2020 (fax 570-453-1020), or refer a patient or ask a question by email. Patients can schedule an exam online.

For privacy, please don’t include patient names or other identifying details in email. Our team will call to schedule and gather details securely.

General contact and referrals: Hazleton Eye Specialists, phone 570-453-2020, fax 570-453-1020. See Referral information for what to send.

References

  1. Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81(13):1159-1165. https://pubmed.ncbi.nlm.nih.gov/23966248/
  2. Mollan SP, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018;89(10):1088-1100. https://pubmed.ncbi.nlm.nih.gov/29903905/
  3. Mollan SP, et al. Effectiveness of bariatric surgery vs community weight management intervention for the treatment of idiopathic intracranial hypertension. JAMA Neurol. 2021;78(6):678-686. https://pubmed.ncbi.nlm.nih.gov/33900360/
  4. Mitchell JL, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023;146(5):1821-1830. https://pubmed.ncbi.nlm.nih.gov/36907221/
  5. NORDIC IIH Study Group Writing Committee. Effect of acetazolamide on visual function in patients with IIH and mild visual loss: the IIH Treatment Trial. JAMA. 2014;311(16):1641-1651. https://pubmed.ncbi.nlm.nih.gov/24756514/

Medical disclaimer. This page is educational and is intended for licensed health care professionals. It is not a clinical practice guideline and does not replace clinical judgment, product labeling, or specialty consultation. Information is current as of the “last reviewed” date.